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Natural killer (NK) cells are an important component of the innate
immune response against viral infections. NK cell-mediated cyto-
lytic activity is defective in HIV-infected individualswith high levels
of viral replication. In the present study, we examined the pheno-
typic and functional characteristics of an unusual CD56CD16
(CD56) NK subset that is greatly expanded in HIV-viremic indi-
viduals. The higher level of expression of inhibitory NK receptors
and the lower level of expression of natural cytotoxicity receptors
observed in the CD56 NK fraction compared with that of CD56
NK cells was associated with extremely poor in vitro cytotoxic
function of this subset. In addition, the secretion of certain cyto-
kines known to be important in initiating antiviral immune re-
sponseswasmarkedly reduced in the CD56, as comparedwith the
CD56NK cell subset. These data suggest that the expansion of this
highly dysfunctional CD56 NK cell subset in HIV-viremic individ-
uals largely accounts for the impaired function of the total NK cell
population.
cytokines  cytotoxicity  inhibitory NK receptors  killer
immunoglobulin-like receptors  natural cytotoxicity receptors
Natural killer (NK) cells, which account for up to 15% ofperipheral blood lymphocytes, are well known as important
effectors of the innate immune system (1, 2). In addition, NK cells
are an important source of cytokines that regulate hematopoiesis
and link the innate to the adaptive immune response through a
bidirectional cross-talk with dendritic cells (3, 4).
NK cells are able to lyse tumor and virally infected cells without
prior sensitization while sparing normal cells that express adequate
levels ofMHCof class Imolecules (MHC-I). This cytolytic function
is under the dominant control of a heterogeneous family of inhib-
itory NK receptors (iNKRs) that bind specifically to certain allelic
forms ofHLAof class I (HLA-I). In humans, the iNKRs are divided
into two different groups: (i) killer immunoglobulin-like receptors
(KIRs); (ii) LIR1ILT2 and NKG2ACD94, which belong to the
family of the C-type lectin proteins. Diminution or absence of
expression of HLA-I molecules on the cell surface because of viral
infection or tumor transformation results in reduced engagement of
iNKRs; loss of this dominant-negative signal in turn allows a large
group of activating NK receptors and coreceptors to trigger cyto-
lytic activity (5–7).
The role of NK cells in the course of HIV-1 infection remains to
be fully elucidated; however, the effect of HIV infection on NK cell
function has been increasingly delineated in recent years. It is well
documented that NK cells isolated from HIV-infected individuals
are impaired in their ability to kill HIV-1-infected autologous cells,
as well as tumor cell lines (8–11). More recently, numerous studies
have characterized the effects of HIV viremia on NK cell pheno-
type and function. In this regard, it has been demonstrated that the
expression and function ofmostmajor iNKRs are eithermaintained
or significantly increased on the surface of NK cells in viremic
patients (12, 13), and a direct correlation has been reported
between these findings and levels of HIV viremia (14). Moreover,
the expression of natural cytotoxicity receptors (NCRs), NKp46,
NKp30, and NKp44, is markedly decreased among viremic indi-
viduals, along with a concomitant decrease in NK cytolytic activity
(13, 15). In addition, HIV viremia affects the capacity of NK cells
to secrete CC-chemokines, which are well known as suppressors of
HIV replication ex vivo (16, 17). Finally, the expansion of an
unusual CD56CD16 (CD56) NK cell subset has been associ-
ated with high HIV viral loads (10, 13, 18). The successful sup-
pression of HIV replication below detectable levels after treatment
with effective antiretroviral therapy results in considerable im-
provement of NK cell cytotoxicity, cytokine secretion, NK cell
receptor expression and function (13), and the restoration of
normal CD56 expression (19).
The present study characterizes the phenotypic and functional
characteristics of the CD56 NK subset isolated from HIV-1-
viremic individuals. This population exhibited significantly lower
cytolytic activity and ability to secrete cytokines, as well as more
dramatic abnormalities in the expression and function of NK
activating and inhibiting receptors when compared with the CD56
NK cell subset from the same individuals. These data suggest that
impairments observed in the total NK population of HIV-viremic
individuals are largely due to elevated frequencies of this highly
dysfunctional CD56 NK cell subset.
Methods
Study Subjects. Forty-eight HIV-1-infected viremic individuals who
were not receiving antiretroviral therapy were studied. The median
CD4 cell count was 552 per l (SD  251) and the CD4CD8
ratio was1 in all subjects. The median plasma viremia was 36,249
HIV RNA copies (SD70,952) per ml of plasma as detected by
an ultrasensitive branched DNA (bDNA) assay (Chiron) with a
lower limit of detection of 50 copies per ml (Table 1, which is
published as supporting information on the PNAS web site).
Leukapheresis was performed after signed informed consent was
given as part of clinical protocols approved by Institutional Review
Boards of the University of Toronto (21 patients) and of the
National Institute of Allergy and Infectious Diseases (27 patients).
As negative controls, peripheral bloodmononuclear cells (PBMCs)
from 30 healthy donors seronegative for HIV were obtained by
apheresis generously provided by the Transfusion Medicine De-
partment of theWarrenGrantMagnusonClinical Center, National
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Institutes of Health. The normal donors were enrolled under a
protocol approved by the Institutional Review Board. The median
CD4 T cell count was 1,620 cells per l (SD  299) and the
CD4CD8 ratio was 1 in all of the subjects.
Isolation and Culture of NK Cells. PBMCs were isolated over Ficoll–
Hypaque gradients (LSM, ICN), and NK cells were isolated by
negative selection using column-based cell separation techniques
(Stem Cell Technologies, Vancouver), as described in refs. 13 and
17. Purified NK cells contained 3% contamination of other
PBMC subsets (CD3, CD4, TCR, TCR, CD19, or CD14).
CD56 and CD56 NK cell subsets were separated by using a
magnetic cell-sorting technique (MACS, Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the protocol provided by the
manufacturer. The purities of the CD56 and CD56 NK cell
fractions, as assessed by flow cytometry, were consistently more
than 95% and 90%, respectively. CD56 and CD56 NK cell
subsets were placed in 96-well round-bottom plates at a concen-
tration of 106 cells perml and activated for 6 days inmedium (RPMI
medium 1640 with penicillinstreptomycin, L-glutamine (GIBCO),
and 10% FCS (HyClone) containing recombinant IL-2 (rIL-2) at
200 unitsml (Roche Molecular Biochemicals).
Monoclonal Antibodies (mAbs). The mAbs 289 (IgG2a anti-CD3),
C218 and FS280 (IgG1 and IgG2a anti-CD56, respectively), KD1
(IgG2a anti-CD16), Gl183 (IgG1 anti-p58.2KIR2DL2), 11pb6
(IgG1 anti-p58.1KIR2DL1), Z27 (IgG1 anti-p70KIR3DL1),
F278 (IgG1 anti-LIR1ILT2), Z270 (IgG1 anti-NKG2A), Xa185
(IgG1 anti-CD94), Q66 (IgM anti-p140KI3DL2), Qa79 (IgG1
anti-p75AIRM1), Bab281 (IgG1 anti-NKp46), Az20 (IgG1 anti-
NKp30), Z231 (IgG1 anti-NKp44), On72 and Bat221 (IgG1 anti-
NKG2D), pp35 (IgG1 anti-2B4), Ma152 (IgG1 anti-NKp80), and
Ma127 (IgG1 anti-NTB-A) were provided by one of the authors
(A.M.) and D. Pende (Istituto Scientifico Tumori, Genoa, Italy).
Anti-CD4 (IgG1), anti-TCR (IgG1), anti-TCR  (IgG1), anti
CD19 (IgG1), anti-CD14 (IgG1), anti-CD69 (IgG1), and anti CD38
(IgG1) were purchased from BD Pharmingen.
Flow-Cytometric Analysis and Cytolytic Activity.For one or two-color
cytofluorimetric analysis, freshly isolated and rIL-2-activated NK
cells were stained with the appropriate mAbs followed by phyco-
erythrin (PE)- or FITC-conjugated isotype-specific goat anti-
mouse second reagent (Southern Biotechnology Associates). Sec-
ond appropriate anti-isotypic mAbs stained with PE orand FITC
were used as negative controls. The data were analyzed by using
CELLQUEST software (BectonDickinson). After 6 days of activation
with rIL-2, NK cells were tested for cytolytic activity at various
effector-to-target (ET) ratios in a 4-h 51Cr-release assay, as
described in ref. 13.
Cellular Proliferation and Apoptosis of Activated NK Cells. After 6
days of activation with rIL-2, proliferation of CD56 and CD56
NK cell subsets was measured by [3H]thymidine uptake (16 h) in
triplicate. Early apoptotic cells were detected by using a flow-
cytometric assay with FITC-conjugated annexin V according to the
supplier’s instructions (BD Pharmingen).
IFN-, GranulocyteMacrophage Colony-Stimulating Factor (GM-CSF),
and TNF- Secretion by Activated NK Cells.After 6 days of activation
with rIL-2, total unfractionated NK cells, as well as CD56 and
CD56 NK subsets, were stimulated overnight with phytohemag-
glutinin (0.5%), and the levels of supernatant-associated IFN-,
GM-CSF, and TNF- were measured by ELISA according to the
protocol provided by the supplier (R & D Systems).
Statistical Analysis. The distributions of each immune response
variable were compared between uninfected and HIV-infected
viremic individuals by using the Mann–Whitney test. For each
individual, immune response variables were calculated for CD56
and CD16 NK subsets, and the difference in these two variables
was evaluated by using theWilcoxon signed-ranks test. All P values
are two-sided and unadjusted.
Results
Frequency of CD56 Cells in Freshly Isolated NK Cells from HIV-Viremic
Individuals. We have previously shown that the CD56 NK cell
subset, which is rarely observed in uninfected individuals, is ex-
panded in HIV-infected subjects in association with high levels of
plasma viremia (13). In the present study, freshly isolated NK cells
purified from PBMCs of healthy donors and HIV-infected viremic
individuals were analyzed by flow cytometry for the expression of
CD56 and CD16 cell surface markers. Forty-three of 48 (89%)
infected patients with high viral load (Table 1), and 1 of 30 normal
volunteersmanifested aCD56NKcell subset frequency of10%.
The median percentage of the CD56 subset of NK cells isolated
from HIV-viremic versus HIV-negative control subjects was sig-
nificantly different (P  0.0001) (Fig. 4, which is published as
supporting information on the PNAS web site). As previously
described (13, 20), the frequency of CD56brightCD16 NK cells in
PBMCs was not significantly different between healthy donors and
viremic patients (data not shown). HIV-infected individuals whose
viremia was suppressed by antiretroviral therapy for 2 years or
longer showed aNKcell phenotype similar to that of healthy donors
for CD56 and CD16 expression (13).
We and others have reported that the expression and function of
inhibiting and activating NK receptors are dysregulated in NK cells
ofHIV-infected viremic individuals (12–15). To determinewhether
this abnormal expression of NK receptors was preferentially asso-
ciated with a particular NK subset, we analyzed their expression on
CD56 andCD56 populations of freshly isolatedNKcells by using
flow cytometry. The CD56 analysis gate included both the
CD56dimCD16, sharply decreased in viremic individuals (13),
and the CD56brightCD16 NK subpopulations. The expression of
two iNKRs (p58.2KIR2DL2 and LIRILT2) was significantly
higher on CD56, as compared with CD56, NK cells (P  0.016
and P  0.0001, respectively). There was no significant difference
in the levels of expression of the other two major iNKRs (p58.1
KIR2DL1 and p70KIR3DL1) on CD56 versus CD56NK cells;
however, some HIV-viremic subjects exhibited an unusually high
frequency of CD56 cells positive for these KIRs (up to 73%). To
better appreciate the extent of the expansion of the CD56
iNKRs NK subset in viremic patients, the above-mentioned four
iNKRs were labeled all together and analyzed in a double cytoflu-
orometric analysis with the CD56 marker. This dysfunctional
CD56 NK subset showed a statistically significant higher expres-
sion (range 52–83%) of iNKRs when compared with those seen in
the CD56 cells (range 24–76%) (P 0.0001). NKG2A is the only
iNKR that has been previously reported to be decreased in both
expression and function in NK cells from viremic individuals (13).
Of interest, NKG2A expression was significantly lower in the
CD56, as compared with the CD56, subset of NK cells (P 
0.0001). CD94, which, if associated with NKG2A, confers iNKR
activity to the complex, was not differentially expressed on CD56
or CD56 subpopulations (Fig. 5 A and B, which is published as
supporting information on thePNASweb site).Nodifferenceswere
detected in surface expression between the two different subsets of
CD56 and CD56 NK cells for other iNKRs such as p140
KIR3DL2 and p75AIRM1 (data not shown).
We then analyzed the cell surface expression of NKp46, NKp30,
and NKG2D, the main activating receptors that are present con-
stitutively on fresh NK cells. The NCRs NKp46 and NKp30 are
specifically expressed on NK cells, whereas NKG2D is also ex-
pressed on a subset of CD3CD8 T cells (6). NKp46 and NKp30
were barely detectable on theCD56NKsubset, and this frequency
was significantly lower than that observed in the CD56 NK cell
subset (P 0.0001). NKG2Dexpression was comparable in the two









subsets) (Fig. 5 C and D). No differences were observed between
CD56 and CD56NK cells in surface expression of the activating
coreceptors NKp80, 2B4, and NTB-A (data not shown).
Phenotypic and Functional Profiles of CD56 NK Cells after Activation
with rIL-2. Purified CD56 andCD56NK cells fromHIV-infected
viremic individuals were activated in vitro with rIL-2. Expression of
the CD56 molecule was fully recovered upon activation of the
CD56 subset over the course of 2–3 weeks (Fig. 1A). Despite the
partial reversion of the CD56 subset to a CD56 phenotype after
6 days of rIL-2 stimulation, the cytolytic activity of these cells
against the NK-susceptible K562 erythroleukemia cell line target
was dramatically reduced compared with that of the activated
CD56NK cell subset of the sameHIV donor (P 0.05) (Fig. 1B).
K562-directed killing by this population did not significantly im-
prove even after 21 days of activation although cells expressed
normal levels of classical markers of activation, such as CD69 or
CD38 (data not shown) and a complete recovery of CD56 as shown
in Fig. 3A. Moreover, the frequency of the entire CD56 and
CD56 freshly derived NK subsets that were undergoing apoptosis
(annexin V-positive cells) during the course of activation was low
(Fig. 1C). In addition, the level of cellular proliferation of the
CD56 subset after 6 days of culture with rIL-2 did not differ
significantly from that of the CD56 subset (P  0.05) (Fig. 1D).
Finally, therewere nodifferences between these subsets with regard
to the secretion of perforin or granzyme (data not shown).
Functional Correlates of Inhibiting and Activating NK Receptor Ex-
pression on Activated CD56 and CD56 NK Cells. Using mAbs with
activating properties directed against specific iNKRs and NCRs
(redirected killing assays), we sought to determinewhether cytolytic
activity could be correlated with NK receptor expression on acti-
vated CD56- or CD56-derived NK cells. After 6 days of stimu-
lation with rIL-2, the frequency of expression of iNKRs on the
CD56-positive- and negative-derived NK cells was very similar to
that seen in freshly isolated subsets, and the differences observed
between fresh CD56 and CD56 NK subsets in receptor expres-
sion remained statistically significant (Fig. 6 A and B, which is
published as supporting information on the PNAS web site). To
evaluate whether the level of each inhibiting NK receptor was
related to its function, CD56 and CD56 activated NK subsets
were analyzed in a redirected killing assay against the FcR P815
target cell line in the presence of anti-CD16 mAb, used alone or in
combination with mAb specific for each individual iNKR. The
increased expression of one or another inhibitory NK cell receptor
on the activated CD56 NK subset was always associated with a
greater inhibition of the CD16-induced cytotoxicity when com-
pared with that of the CD56 NK cells, which had a lower
expression of iNKRs. The higher levels of the iNKRs p58.2
KIR2DL2 (Fig. 2A) andLIR1ILT2 (not shown) on theCD56NK
subset were associated with significantly greater inhibition of lytic
activity by this population, as compared with that of the CD56NK
subset, in CD16-induced redirected killing assays (P  0.05). This
result also indicated that theKIRmolecules detected byGl183mAb
Fig. 1. CD56 phenotype and function of activated CD56 NK cells. (A) Separation of CD56 and CD56 subsets in total freshly isolated NK cells obtained from
a viremic HIV-infected patient and recovery of CD56 expression upon stimulation with rIL-2 in vitro. (B) Spontaneous cytolytic activity against the K562 cell line
of NK cells activated with rIL-2 for 6 days at various effector-to-target (ET) ratios. Data represent the average lytic activity obtained by using CD56 (green
squares) versus CD56 (red circles) NK cells from 48 HIV-viremic patients. (C) Representative example of cytofluorometric analysis with CD56-PEannexin V-FITC
of CD56 (left green plot) and CD56 (right red plot) NK cells after 6 days of stimulation with rIL-2. (D) Proliferation of CD56 (green diamond) and CD56 (red
circle) NK cell subsets at different cell numbers per well after stimulation with rIL-2 for 6 days. Data are represented as the average [3H]thymidine cpm of
experiments conducted with cells from 48 patients.
2888  www.pnas.orgcgidoi10.1073pnas.0409872102 Mavilio et al.
(which reacts with both KIR2DL2 and KIR2DL3) within the
CD56 NK subset are essentially represented by inhibitory rather
than activating forms of KIRs. Suppression of lytic activity by
p58.1KIR2DL1 and p70KIR3DL1 was similar between the
CD56 and CD56NK subsets, reflecting the comparable levels of
expression of these iNKRs on the two NK populations (data not
shown). Finally, the addition of anti-NKG2AmAb had a significant
(P 0.05) inhibitory effect on the lytic activity of CD56-, but not
CD56-, activated NK cells (Fig. 2B), a result that correlates with
the very low or negative expression of NKG2A on the CD56 cells.
Similar to the expression of iNKRs, the differential expression of
the activating NK receptors, NKp46 and NKp30, on fresh CD56
and CD56 cells did not change significantly over the course of
activation (Fig. 3 A and B). NKp44, a NK cell-specific NCR usually
expressed only upon activation (6), resulted in up-regulation on the
surface of CD56, but not CD56, NK cells, after 6 days of
stimulation with rIL-2 (P  0.0003) (Fig. 3C). To evaluate the
functional capability of NCRs to induce NK-mediated cytotoxicity,
activated NK subsets derived from CD56 and CD56 cells were
analyzed in a redirected killing assay in the presence or absence of
mAbs specific for NKp46, NKp30, and NKp44. In cultures con-
taining activated CD56 NK cells none of the three NCR mAbs
were able to induce NK-mediated cytotoxicity, consistent with the
NCRsdim or NCRsneg phenotype of these cells. In contrast, CD56
NK cells, which express these NCRs to various degrees, exhibited
enhanced cytolytic activity (P  0.05) after mAb-mediated activa-
tion of NKp46, NKp30, and NKp44 (Fig. 3).
Therefore, despite the recovery of CD56 expression on the
CD56 NK subset in a time-dependent manner upon stimulation
with rIL-2, this unusual population kept the identical profile of
expression of activating and inhibiting NK receptors over the time
period in question. This conserved phenotype allowed us to exclude
anymajor contamination of the CD56 cell subset with CD56NK
cells during the growth and proliferation of the CD56 population.
In this regard, in the NK subset separation shown as a represen-
tative example in Fig. 1A, the CD56 expression on the freshly
purifiedCD56NKcells was only of 2.5%.Onactivationwith rIL-2,
the CD56-derived NK cells, whose rate of proliferation and
apoptosis did not differ from that of the CD56-derived NK cells,
had similar levels of p58.2KIR2DL2 as well as a similar lack of
expression of NKG2ACD94 and NCRs noted in the original fresh
CD56NK cells. In a similar manner, the activated CD56-derived
NK cells kept the same phenotype of the freshly purified CD56
cells (Figs. 2 and 3). Moreover, the same striking differences in NK
receptor levels between fresh CD56 and CD56 cells were con-
served on the activated cells, reflecting the extreme dichotomy of
cytolytic activities of the two subsets (Fig. 6).
IFN-, TNF-, and GM-CSF Secretion. In addition to lytic activity, NK
cells release several cytokines that can modulate other effector
functions of the immune system (3, 21). The levels of a large panel
of NK-related cytokines were assessed in the supernatants from
cultures of total unfractionated, CD56, and CD56NK cells after
6 days of stimulation with rIL-2 and 12 h with phytohemagglutinin.
As reported by several studies (13, 22–24), activated NK cells from
HIV-viremic patients secrete significantly lower levels of IFN-,
TNF-, and GM-CSF as compared with NK cells isolated from
healthy donors. Furthermore, within the cohort of viremic subjects,
activated NK cells derived from fresh CD56 cells produced
significantly lower levels of IFN-, TNF-, and GM-CSF as com-
pared with the levels secreted by activated CD56NK cells (Fig. 7,
which is published as supporting information on the PNAS web
site).
Discussion
NK cell functions are significantly impaired in HIV-infected indi-
viduals with high levels of ongoing viral replication. In healthy
HIV-seronegative individuals, as well as in HIV-infected individ-
uals who are receiving antiretroviral therapy andwhose viremia was
suppressed to below detectable level for 2 years or longer, the
majority of NK cells (85–95%) are CD56dimCD16, whereas a
minority are CD56bright and CD16dim/neg cells (13, 25). When the
HIV viral load is high, there is a dramatic expansion of CD56
CD16 (CD56) NK cells, a subset that is represented at a very low
frequency in healthy HIV-negative and aviremic HIV-infected
individuals (10, 13, 18). Of note, HIV-1 viremia does not seem to
affect the CD56bright NK cells; however, it is associated with a
statistically significant decrease of the CD56dimCD16 NK sub-
population (13, 20), and it has also been related to a rapid and early
progression to AIDS (26). The presence of an expanded CD56
NK cell population among HIV viremic individuals has been
associated with significantly reduced spontaneous NK cytolytic
activity as compared with that of aviremic individuals or healthy
Fig. 2. Expression and function of iNKRs p58.2KIR2DL2 and NKG2A on
CD56 and CD56 NK cell subsets. CD56 (Upper) and CD56 (Lower) NK cell
subsets were analyzed for iNKRs expression (Left) and function (Right). His-
tograms indicate the percent of freshly isolated (solid red) or rIL-2-activated
(blue lines) CD56and CD56NK cells expressing p58.2KIR2DL2 (A) or NKG2A
(B). Functional evaluation of iNKRs by a redirected killing assay using an FcR
P815 target cell line and IL-2-activated NK cell subsets are adjacent to each
histogram. Every graph shows the baseline lysis (blue squares), the maximal
lysis triggered by anti-CD16 IgG mAb (blue diamonds), and the inhibition of
killing driven by the cotriggering of relevant receptors with anti-CD16 IgG
mAb (red circles). Data are from a single experiment and are representative of
data obtained by using cells isolated from 48 HIV-viremic patients.









donors (13). The present study delineates the potential mechanisms
of these abnormalities by demonstrating that the expression of
NCRs is low or negative whereas that of certain iNKRs is elevated
on the CD56, as compared with the CD56, NK cell subset
isolated from HIV-infected viremic subjects. In addition, the im-
paired cytolytic function of CD56 NK cells reflects the aberrant
expression of certainNK receptors on this subset. Furthermore, the
production of numerous cytokines known to modulate the function
of other immune effectors was reduced in the CD56, as compared
with the CD56NK cell subset. Taken together, these data suggest
that impaired NK cell function in HIV-infected viremic individuals
may be largely attributable to the expansion of this highly dysfunc-
tional CD56 NK cell subset.
Significant differences in spontaneous cytolytic activity between
the CD56 and CD56 NK cells isolated from HIV-infected
individuals have been previously reported (27). The present study
confirmed that the CD56 NK subset isolated from HIV-viremic
individuals exhibits very low cytotoxicity against K562 targets, even
after the complete recovery of the expression of CD56 upon
activation with rIL-2. We were unable to identify significant dif-
ferences between rIL-2-activatedCD56 andCD56NK subsets in
terms of cellular proliferation or perforingranzyme expression; in
addition, rates of apoptosis were low in both subsets. However, a
striking correlation was observed between the cytolytic dysfunction
of CD56 NK cells and the expression of activating and inhibiting
NK receptors on this subset.
In a previous study we noted that the expression of certain
iNKRs, such as the inhibitory forms of KIRs and LIR1ILT2, are
either conserved or increased on NK cells from HIV viremic
patients, as comparedwithHIV-negative or aviremicHIV-infected
subjects who had been receiving antiretroviral therapy for 2 years
or more, with the exception of NKG2A, which is decreased (13). In
the present study, we have demonstrated that the level of expression
of iNKRs wasmuch higher on the CD56NK cell subset compared
with the CD56 NK cell subset isolated from the same HIV-1-
viremic individuals. Furthermore, functional analysis confirmed the
greater receptor-specific inhibition of CD16-mediated cytolytic
activity in CD56NK cells consistent with the increased expression
of iNKRs on their cell surface. The relevance of elevated iNKR
expressionfunction in the context of HIV-infected target cells is
suggested by the observation that, despite the selective decrease of
MHC-I expression that generally occurs in HIV infection in vitro
(28), NK cells are not able to lyse autologous infected T cell blasts
(11) unless the interaction between specific HLAs and the corre-
sponding iNKR is blocked (29). Clearly, the elevated expression of
certain, but not all, iNKRs on CD56 NK cells in parallel with
HIV-mediated down-regulation of MHC-I molecules presents a
complex scenario.
If the dominant-negative effects of iNKR-self MHC-I interac-
tions are overcome as would be expected by the virus-induced
down-regulation of MHC-1 molecules, the triggering of activating
NCRs by their ligands induces NK cytolytic activity. In this regard,
the low or absent expression of NK-specific NCRs on CD56 NK
cells versus CD56 NK cells was more striking than the higher
expression of iNKRs on CD56 versus CD56 NK cells. A signif-
icant proportion of fresh andor activated CD56 NK cells ex-
pressed the three NCRs, NKp46, NKp30, and NKp44, and this
subset of NK cells was able to lyse target cells through these
activating receptors. In contrast, CD56NK cells were negative for
or had a very low surface density of these NCRs and almost a
complete lack of ability to respond to NCR antibody-mediatedFig. 3. Expression and function of NCRs on CD56
 and CD56NK cell subsets.
CD56 (Upper) and CD56 (Lower) NK cell subsets were analyzed for NCR
expression (Left) and function (Right). Histograms indicate the percent of
freshly isolated (solid red) or rIL-2-activated (blue lines) CD56 and CD56 NK
cells expressing NKp46 (A), NKp30 (B), and NKp44 (C). The percentage of NK
cells expressing NCRs with their geometric mean fluorescence intensity (MF)
are indicated. Functional evaluation of NCRs by a redirected killing assay using
an FcR P815 target cell line and IL-2-activated NK cell subsets are adjacent
to each histogram. Every graph shows the baseline lysis (blue squares), the
maximal lysis triggered by anti-CD16 IgG mAb (blue diamonds), and killing
driven by the relevant activating NK receptors (red circles). Data are from a
single experiment and are representative of data obtained by using cells
isolated from 48 HIV-viremic patients whose expression and function of NCRs
were similar.
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triggering of cytotoxicity.While it remains unclear what the relative
role of NK cells is in controlling ongoing HIV replication, the
marked diminution of activating NCRs on the CD56 population
could certainly contribute to a reduced ability to eliminate virus-
infected cells. In this regard, it has been shown that immature
dendritic cells of HIV-infected individuals are able to escape NK
cell-mediated killing (30), an activity that in healthy individuals has
been reported to be mainly dependent on the engagement of
NKp30 receptor (31).
The mechanism(s) whereby the expression of certain NK recep-
tors is dysregulated on CD56NK cells of HIV-viremic individuals
is not clear. Several cytokines have been shown to modulate the
expression of NK receptors and some, such as TGF-, which
down-regulates the levels ofNKp30 (32), and IL-10, which increases
the expression of several iNKRs (33), have been found to be present
at elevated levels in the serum of AIDS patients (34–36). We did
not find significant differences in the levels of TGF- (13) or IL-10
(data not shown) secreted by NK cells from viremic individuals
compared with those of healthy donors, suggesting that at least an
autocrinemechanismof receptormodulation amongNKcells is not
likely. However, NK cells are not the only cell types capable of
producing these cytokines. Alternatively, CD56 down-regulation
and altered expression of NCRs and iNKRs may reflect persistent
antigenic exposure and a general state of chronic cellular activation
seen with the HIV viremic state (37, 38). However, the expansion
of the CD56CD16 NK subset in HIV-infected individuals
appears to be strictly associated withHIV viremia and has not been
described in any other viral infections or immunological diseases
that are associated with an aberrant state of immune activation.We
have previously demonstrated that the NK subsets isolated in our
studies are negative for HIV DNA, ruling out possible effects of
direct viral infection (13). However, it remains possible that direct
physical interaction between HIV virions or viral products and NK
cells by means of chemokine receptors or C-lectin type receptors
may result in dysregulation of NK receptors.
NK cells are an important component of the innate immune
response to viral infection; however, they also secrete several
cytokines and chemokines that play a role in the recruitment and
activation of the adaptive immune response (39, 40). IFN-, TNF-,
andGM-CSF can play a role in activating antiviral activities of other
cell types (41); however, they can also promote the maturation and
migration of dendritic cells, allowing effective antigen-presentation
for the adaptive immune response (3, 21). A significant reduction
in levels of IFN-, TNF-, andGM-CSFproduced byNKcells from
viremic patients versus healthy donors has been previously reported
(13, 22–24). The present study demonstrates that the CD56 NK
subset is particularly impaired in its ability to produce these
cytokines. Thus, it remains to be determined whether this defect in
cytokine secretion is related to a defect in triggering of NCRs and
whether this defect also has an impact on dendritic cell function in
HIV disease.
In conclusion, the present study describes the phenotypic and
functional characteristics of the CD56CD16 subset of NK cells,
a population that is present at high frequencies in viremic individ-
uals but not in aviremic HIV-infected individuals or healthy donors
(13). As the CD56 NK subset from these individuals appeared to
be relatively intact with regard to NK receptor expression and
function, we believe that the dramatic expansion of highly dysfunc-
tional CD56 NK cells likely accounts for the defects previously
reported for total NK cell populations from HIV-viremic individ-
uals. Additional studies will be needed to further verify the HIV
specificity of CD56CD16 NK cell expansion and to elucidate
the molecular mechanism(s) that drive the dysregulation of NK
receptor expression and function in this subset.
This work is dedicated to the memory of Angelo Mavilio. We thank the
patients for their participation in this study.We also thank ShyamKottilil
for his invaluable assistance in reviewing the manuscript.
1. Karre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. (1986) Nature 319, 675–678.
2. Trinchieri, G. (1989) Adv. Immunol. 47, 187–376.
3. Moretta, A. (2002) Nat. Rev. Immunol. 2, 957–964.
4. Raulet, D. H. (2004) Nat. Immunol. 5, 996–1002.
5. Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C. &
Moretta, L. (1996) Annu. Rev. Immunol. 14, 619–648.
6. Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni,
R. & Moretta, L. (2001) Annu. Rev. Immunol. 19, 197–223.
7. Cerwenka, A. & Lanier, L. L. (2001) Nat. Rev. Immunol. 1, 41–49.
8. Ullum, H., Gotzsche, P. C., Victor, J., Dickmeiss, E., Skinhoj, P. & Pedersen, B. K.
(1995) J. Exp. Med. 182, 789–799.
9. Ahmad, A. & Menezes, J. (1996) AIDS 10, 143–149.
10. Scott-Algara, D. & Paul, P. (2002) Curr. Mol. Med. 2, 757–768.
11. Bonaparte, M. I. & Barker, E. (2003) AIDS 17, 487–494.
12. Ahmad, R., Sindhu, S. T., Tran, P., Toma, E., Morisset, R., Menezes, J. & Ahmad,
A. (2001) J. Med. Virol. 65, 431–440.
13. Mavilio, D., Benjamin, J., Daucher, M., Lombardo, G., Kottilil, S., Planta, M. A.,
Marcenaro, E., Bottino, C., Moretta, L., Moretta, A. & Fauci, A. S. (2003) Proc. Natl.
Acad. Sci. USA 100, 15011–15016.
14. Kottilil, S., Shin, K., Planta, M., McLaughlin, M., Hallahan, C. W., Ghany, M., Chun,
T. W., Sneller, M. C. & Fauci, A. S. (2004) J. Infect. Dis. 189, 1193–1198.
15. De Maria, A., Fogli, M., Costa, P., Murdaca, G., Puppo, F., Mavilio, D., Moretta, A.
& Moretta, L. (2003) Eur. J. Immunol. 33, 2410–2418.
16. Oliva, A., Kinter, A. L., Vaccarezza, M., Rubbert, A., Catanzaro, A., Moir, S.,
Monaco, J., Ehler, L., Mizell, S., Jackson, R., et al. (1998) J. Clin. Invest. 102, 223–231.
17. Kottilil, S., Chun, T. W., Moir, S., Liu, S., McLaughlin, M., Hallahan, C. W.,
Maldarelli, F., Corey, L. & Fauci, A. S. (2003) J. Infect. Dis. 187, 1038–1045.
18. Hu, P. F., Hultin, L. E., Hultin, P., Hausner, M. A., Hirji, K., Jewett, A., Bonavida,
B., Detels, R. & Giorgi, J. V. (1995) J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
10, 331–340.
19. Sondergaard, S. R., Aladdin, H., Ullum, H., Gerstoft, J., Skinhoj, P. & Pedersen, B. K.
(1999) J. Acquir. Immune Defic. Syndr. 21, 376–383.
20. Tarazona, R., Casado, J. G., Delarosa, O., Torre-Cisneros, J., Villanueva, J. L.,
Sanchez, B., Galiani, M. D., Gonzalez, R., Solana, R. & Pena, J. (2002) J. Clin
Immunol. 22, 176–183.
21. Cooper, M. A., Fehniger, T. A., Fuchs, A., Colonna, M. & Caligiuri, M. A. (2004)
Trends Immunol. 25, 47–52.
22. Scott-Algara, D., Vuillier, F., Cayota, A. & Dighiero, G. (1992) Clin. Exp. Immunol.
90, 181–187.
23. Azzoni, L., Papasavvas, E., Chehimi, J., Kostman, J. R., Mounzer, K., Ondercin, J.,
Perussia, B. & Montaner, L. J. (2002) J. Immunol. 168, 5764–5770.
24. Jacobs, R., Weber, K., Wendt, K., Heiken, H. & Schmidt, R. E. (2004) J. Clin.
Immunol. 24, 281–286.
25. Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur,
T., Carson, W. E. & Caligiuri, M. A. (2001) Blood 97, 3146–3151.
26. Bruunsgaard, H., Pedersen, C., Skinhoj, P. & Pedersen, B. K. (1997) Scand.
J. Immunol. 46, 91–95.
27. Sondergaard, S. R., Ullum, H. & Pedersen, B. K. (2000) APMIS 108, 831–
837.
28. Cohen, G. B., Gandhi, R. T., Davis, D. M., Mandelboim, O., Chen, B. K., Strominger,
J. L. & Baltimore, D. (1999) Immunity 10, 661–671.
29. Bonaparte, M. I. & Barker, E. (2004) Blood 104, 2087–2094.
30. Tasca, S., Tambussi, G., Nozza, S., Capiluppi, B., Zocchi, M. R., Soldini, L., Veglia,
F., Poli, G., Lazzarin, A. & Fortis, C. (2003) AIDS 17, 2291–2298.
31. Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M. & Munz, C.
(2002) J. Exp. Med. 195, 343–351.
32. Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R.,
Biassoni, R., Bottino, C., Moretta, L. &Moretta, A. (2003) Proc. Natl. Acad. Sci. USA
100, 4120–4125.
33. Parato, K. G., Kumar, A., Badley, A. D., Sanchez-Dardon, J. L., Chambers, K. A.,
Young, C. D., Lim, W. T., Kravcik, S., Cameron, D. W. & Angel, J. B. (2002) AIDS
16, 1251–1256.
34. Lotz, M. & Seth, P. (1993) Ann. N.Y. Acad. Sci. 685, 501–511.
35. Stylianou, E., Aukrust, P., Kvale, D., Muller, F. & Froland, S. S. (1999) Clin. Exp.
Immunol. 116, 115–120.
36. Havlir, D. V., Torriani, F. J., Schrier, R. D., Huang, J. Y., Lederman, M. M.,
Chervenak, K. A. & Boom, W. H. (2001) J. Clin. Microbiol. 39, 298–303.
37. Chun, T. W., Justement, J. S., Sanford, C., Hallahan, C. W., Planta, M. A., Loutfy,
M., Kottilil, S., Moir, S., Kovacs, C. & Fauci, A. S. (2004) Proc. Natl. Acad. Sci. USA
101, 2464–2469.
38. Fogli, M., Costa, P., Murdaca, G., Setti, M., Mingari, M. C., Moretta, L., Moretta,
A. & De Maria, A. (2004) Eur. J. Immunol. 34, 2313–2321.
39. Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. (2001) Trends Immunol. 22,
633–640.
40. Robertson, M. J. (2002) J. Leukocyte Biol. 71, 173–183.
41. Ahmad, A. & Ahmad, R. (2003) Curr. HIV Res. 1, 295–307.
Mavilio et al. PNAS  February 22, 2005  vol. 102  no. 8  2891
IM
M
U
N
O
LO
G
Y
